Why the study?
Does argatroban provide a predictable pharmacokinetic-pharmacodynamic relationship in patients undergoing elective PCI?
Does argatroban provide a predictable pharmacokinetic-pharmacodynamic relationship in patients undergoing elective PCI?
Argatroban demonstrates a predictable dose-effect relationship and small interindividual variability in pharmacokinetic and pharmacodynamic properties during elective PCI.
No takes yet. Share an insight, caveat, or question.
Argatroban supports reliable anticoagulation in elective PCI; extends PK-PD evidence confirming low interindividual variability.
Akimoto et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: